Blockage of drug resistance in vitro by disulfiram, a drug used to treat alcoholism

Journal of the National Cancer Institute

Volumn 92, Issue 11, 2000, Pages 898-902

  Loo, Tip W ^b   Clarke, David M ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ADENOSINE TRIPHOSPHATASE; COLCHICINE; CYSTEINE; CYTOTOXIC AGENT; DISULFIRAM; GLYCOPROTEIN P; HYGROMYCIN B; MUTANT PROTEIN; RECOMBINANT PROTEIN; VINBLASTINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALCOHOLISM; ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG SENSITIVITY; EMBRYO; ENZYME ASSAY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY CELL; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN PROCESSING;

EID: 0034616637     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/92.11.898     Document Type: Article

References (33)

1. Lehnert M. Clinical multidrug resistance in cancer: a multifactorial problem. Eur J Cancer 1996;6:912-20.
2. Riordan JR, Ling V. Genetic and biochemical characterization of multidrug resistance. Pharmacol Ther 1985;28:51-75.
3. Gros P, Ben Neriah YB, Croop JM, Housman DE. Isolation and expression of a complementary DNA that confers multidrug resistance. Nature 1986; 323:728-31.
4. Higgins CF. ABC transporters: from microorganisms to man. Annu Rev Cell Biol 1992;8:67-113.
5. Goldstein LJ. MDR1 gene expression in solid tumours. Eur J Cancer 1996; 6:1039-50.
6. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 1999;39:361-98.
7. Kim RB, Fromm MF, Wandel C, Leake B, Wood AJ, Roden DM, et al. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 1998;101:289-94.
8. Lee CG, Gottesman MM, Cardarelli CO, Ramachandra M, Jeang KT, Ambudkar SV, et al. HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry 1998;37:3594-601.
9. Chan HS, Grogan TM, DeBoer G, Haddad G, Gallie BL, Ling V. Diagnosis and reversal of multidrug resistance in paediatric cancers. Eur J Cancer 1996;32A:1051-61.
10. Loo TW, Clarke DM. Correction of defective protein kinesis of human P-glycoprotein mutants by substrates and modulators. J Biol Chem 1997; 272:709-12.
11. Loo TW, Clarke DM. Functional consequences of proline mutations in the predicted transmembrane domain of P-glycoprotein. J Biol Chem 1993; 268:3143-9.
12. Loo TW, Clarke DM. Rapid purification of human P-glycoprotein mutants expressed transiently in HEK 293 cells by nickel-chelate chromatography and characterization of their drug-stimulated ATPase activities. J Biol Chem 1995;270:21449-52.
13. Loo TW, Clarke DM. Membrane topology of a cysteine-less mutant of human P-glycoprotein. J Biol Chem 1995;270:843-8.
14. Kunkel TA. Rapid and efficient site-specific mutagenesis without phenotypic selection. Proc Natl Acad Sci U S A 1985;82:488-92.
15. Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci U S A 1977;74:5463-7.
16. Chifflet S, Torriglia A, Chiesa R, Tolosa S. A method for the determination of inorganic phosphate in the presence of labile organic phosphate and high concentrations of protein: application to lens ATPases. Anal Biochem 1988;168:1-4.
17. Akiyama S, Cornwell MM, Kuwano M, Pastan I, Gottesman MM. Most drugs that reverse multidrug resistance also inhibit photoaffinity labeling of P-glycoprotein by a vinblastine analog. Mol Pharmacol 1988;33: 144-7.
18. Loo TW, Clarke DM. Covalent modification of human P-glycoprotein mutants containing a single cysteine in either nucleotide-binding fold abolishes drug-stimulated ATPase activity. J Biol Chem 1995;270:22957-61.
19. Loo TW, Clarke DM. Identification of residues in the drug-binding domain of human P-glycoprotein. Analysis of transmembrane segment 11 by cysteine-scanning mutagenesis and inhibition by dibromobimane. J Biol Chem 1999;274:35388-92.
20. Sato S, Ward CL, Krouse ME, Wine JJ, Kopito RR. Glycerol reverses the misfolding phenotype of the most common cystic fibrosis mutation. J Biol Chem 1996;271:635-8.
21. Brown CR, Hong-Brown LQ, Biwersi J, Verkman AS, Welch WJ. Chemical chaperones correct the mutant phenotype of the delta F508 cystic fibrosis transmembrane conductance regulator protein. Cell Stress Chaperones 1996;1:117-25.
22. Ward CL, Kopito RR. Intracellular turnover of cystic fibrosis transmembrane conductance regulator. Inefficient processing and rapid degradation of wild-type and mutant proteins. J Biol Chem 1994;269:25710-8.
23. Sarkadi B, Muller M. Search for specific inhibitors of multidrug resistance in cancer. Semin Cancer Biol 1997;8:171-82.
24. Hojo M, Morimoto T, Maluccio M, Asano T, Morimoto K, Lagman M, et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 1999;397:530-4.
25. Chick J. Safety issues concerning the use of disulfiram in treating alcohol dependence. Drug Saf 1999;20:427-35.
26. Walker JE, Saraste M, Runswick MJ, Gay NJ. Distantly related sequences in the alpha-and beta-subunits of ATP synthase, myosin, kinases and other ATP-requiring enzymes and a common nucleotide binding fold. EMBO J 1982;1:945-51.
27. al-Shawi MK, Urbatsch IL, Senior AE. Covalent inhibitors of P-glycoprotein ATPase activity. J Biol Chem 1994;269:8986-92.
28. Liu R, Sharom FJ. Site-directed fluorescence labeling of P-glycoprotein on cysteine residues in the nucleotide binding domains. Biochemistry 1996; 35:11865-73.
29. Jornvall H, Hempel J, Vallee B. Structures of human alcohol and aldehyde dehydrogenases. Enzyme 1987;37:5-18.
30. Madan A, Parkinson A, Faiman MD. Identification of the human and rat P450 enzymes responsible for the sulfoxidation of S-methyl N,N-diethylthiolcarbamate (DETC-ME). The terminal step in the bioactivation of disulfiram. Drug Metab Dispos 1995;23:1153-62.
31. Johansson B. A review of the pharmacokinetics and pharmacodynamics of disulfiram and its metabolites. Acta Psychiatr Scand Suppl 1992;369: 15-26.
32. Johnsen J, Morland J. Depot preparations of disulfiram: experimental and clinical results. Acta Psychiatr Scand Suppl 1992;369:27-30.
33. Canadian Pharmacists Association. Compendium of pharmaceuticals and specialties. Ottawa (Canada); 1998.